Adenoid cystic carcinoma of salivary gland – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:31:06 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Adenoid cystic carcinoma of salivary gland – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Effectiveness of Lutetium (177Lu) Vipivotide Tetraxetan for Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-lutetium-177lu-vipivotide-tetraxetan-for-patients-with-recurrent-or-metastatic-adenoid-cystic-carcinoma/ Wed, 29 Apr 2026 14:27:06 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-lutetium-177lu-vipivotide-tetraxetan-for-patients-with-recurrent-or-metastatic-adenoid-cystic-carcinoma/ This clinical trial is focused on studying a type of cancer called adenoid cystic carcinoma, which originates from the salivary glands. The treatment being tested involves a specialized substance known as prostate-specific membrane antigen (PSMA) that is labeled with a radioactive element called Lutetium177. This treatment is delivered as a solution for injection or infusion, known by the name Pluvicto.

The purpose of the study is to evaluate the effectiveness, safety, and tolerability of this treatment in patients who have recurrent or metastatic adenoid cystic carcinoma. The study will involve monitoring patients over a period of time to assess how well the treatment works and how it affects their health. Patients will receive the treatment through an intravenous infusion, which means it will be administered directly into a vein.

Throughout the study, various aspects of the patients’ health will be observed, including their response to the treatment and any side effects they may experience. The study aims to provide valuable information on how this treatment can be used to manage adenoid cystic carcinoma, with a focus on improving the quality of life for those affected by this condition.

]]>